Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations.

To gain insight in spontaneous as well as agonist-induced activation of the human adenosine A2B receptor, we applied a random mutagenesis approach in yeast to create a large number of receptor mutants and selected mutants of interest with a robust screening assay based on growth. The amino acid sequence of 14 mutated receptors was determined. All these mutated receptors displayed constitutive activity. In particular, single-point mutations at T42A, V54L, and F84S and a triple-point mutation at N36S, T42A, and T66A resulted in high constitutive activity. In addition, a C-terminally truncated (after Lys269) mutant, Q214L I230N V240M V250M N254Y T257S K269stop, was highly constitutively active. The T42A, V54L, and F84S mutants showed a considerable decrease, 4.9- to 6.9-fold, in the EC50 value of 5'-N-ethylcarboxamidoadenosine (NECA), an adenosine analog. Combined mutation of I242T, K269R, V284A, and H302Q, as well as F84L together with S95G, resulted in an even greater potency of NECA of 10- and 18-fold, respectively. In fact, all constitutively active mutants had an increased potency for NECA. This suggests that the wild-type (wt) human A2B receptor itself is rather silent, which may explain the low affinity of agonists for this receptor. To verify the ability of the mutant receptors to activate mammalian second messenger systems, cAMP experiments were performed in CHO cells stably expressing the wt and T42A receptors. These experiments confirmed the increased sensitivity of T42A for NECA, because the EC50 values of T42A and the wt receptor were 0.15 +/- 0.04 and 1.3 +/- 0.4 microM, respectively.

[1]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[2]  P. Corvol,et al.  Lessons from constitutively active mutants of G protein-coupled receptors , 2002, Trends in Endocrinology & Metabolism.

[3]  T. Palmer,et al.  Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  G. Milligan,et al.  Ligand Rescue of Constitutively Active Mutant Receptors , 2002, Neurosignals.

[5]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[6]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[7]  A. IJzerman,et al.  Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. , 2000, Molecular pharmacology.

[8]  T. Schwartz,et al.  Selective Elimination of High Constitutive Activity or Chemokine Binding in the Human Herpesvirus 8 Encoded Seven Transmembrane Oncogene ORF74* , 2000, The Journal of Biological Chemistry.

[9]  Y. Oron,et al.  Rapid desensitization of the TRH receptor and persistent desensitization of its constitutively active mutant , 2000, British journal of pharmacology.

[10]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[11]  M. Marzioch,et al.  Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α‐subunit chimeras , 2000, Yeast.

[12]  T. Kenakin,et al.  Quantitative Molecular Pharmacology and Informatics in Drug Discovery , 2000 .

[13]  A. IJzerman,et al.  TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant data. , 1999, Trends in pharmacological sciences.

[14]  A. IJzerman,et al.  Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity , 1999 .

[15]  O. Lichtarge,et al.  C5a Receptor Activation , 1999, The Journal of Biological Chemistry.

[16]  S. Dowell,et al.  A constitutively active G‐protein‐coupled receptor causes mating self‐compatibility in the mushroom Coprinus , 1999, The EMBO journal.

[17]  J. Bockaert,et al.  Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.

[18]  A. Spek,et al.  5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors. , 1999, Journal of medicinal chemistry.

[19]  D. Richter,et al.  Agonist‐Independent Internalization and Activity of a C‐Terminally Truncated Somatostatin Receptor Subtype 2(δ349) , 1999, Journal of neurochemistry.

[20]  S. Rivkees,et al.  Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.

[21]  R. Osman,et al.  A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. , 1998, Molecular pharmacology.

[22]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[23]  S. Moro,et al.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. , 1998, Journal of medicinal chemistry.

[24]  K. Jacobson,et al.  A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. , 1998, Nucleosides & nucleotides.

[25]  F. Cetani,et al.  Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  M. Bastepe,et al.  The long cytoplasmic carboxyl terminus of the prostaglandin E2 receptor EP4 subtype is essential for agonist-induced desensitization. , 1997, Molecular pharmacology.

[27]  A. IJzerman,et al.  Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. , 1996, Molecular pharmacology.

[28]  M. Pausch,et al.  Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway. , 1996, Molecular pharmacology.

[29]  J. Wess,et al.  Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. , 1996, Molecular pharmacology.

[30]  S. Filetti,et al.  Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. , 1996, The Journal of clinical endocrinology and metabolism.

[31]  D. Perez,et al.  The Unique Nature of the Serine Interactions for -Adrenergic Receptor Agonist Binding and Activation (*) , 1996, The Journal of Biological Chemistry.

[32]  A. Willems,et al.  Studies on the transformation of intact yeast cells by the LiAc/SS‐DNA/PEG procedure , 1995, Yeast.

[33]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[34]  M. Geffner,et al.  Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. , 1995, Human molecular genetics.

[35]  A. Porcellini,et al.  Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. , 1994, The Journal of clinical endocrinology and metabolism.

[36]  A. Allgeier,et al.  Germline mutations in the thyrotropin receptor gene cause non–autoimmune autosomal dominant hyperthyroidism , 1994, Nature Genetics.

[37]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[38]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[39]  N. Dhalla,et al.  Molecular and Pharmacological Aspects of the Developing Heart , 2002 .

[40]  D. I. Våge,et al.  Molecular and pharmacological characterization of dominant black coat color in sheep , 1999, Mammalian Genome.

[41]  David E. Gloriam,et al.  GPCRdb: an information system for G protein-coupled receptors , 2015, Nucleic Acids Res..

[42]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[43]  P. Plateau,et al.  Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. , 1995, Analytical biochemistry.